Rallybio (RLYB)
NASDAQ:RLYB
Want to see RLYB full AI Analyst Report?
RLYB Stock Chart & Stats
$9.11
-$0.04(-3.69%)
At close: 4:00 PM EST
$9.11
-$0.04(-3.69%)
Day’s Range― - ―
52-Week Range$2.41 - $17.57
Previous CloseN/A
Volume36.64K
Average Volume (3M)283.42K
Market Cap
$84.27M
Enterprise Value$43.10M
Total Cash (Recent Filing)$46.80M
Total Debt (Recent Filing)$154.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 06, 2026EPS Estimate
-1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding5,300,039
10 Day Avg. Volume220,035
30 Day Avg. Volume283,421
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.53
Price to Sales (P/S)36.02
P/FCF Ratio-1.04
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue50.23
Enterprise Value/Gross Profit50.40
Enterprise Value/Ebitda-1.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe recent workforce reduction plan and sale of REV102 interest should provide cash runway into mid-2027.
Pipeline DevelopmentRallybio will now focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 (C5) with potential applications in treating complement-related diseases.
Regulatory ApprovalPh2 Study Of '212 In Pregnant Women At Higher Risk For FNAIT received green lights from EU's EMA and UK's MHRA, allowing the start of the trial.
Bears Say
Clinical Trial SetbacksRLYB212 failed to meet the minimum target PK concentration and there is not enough data to accurately dose adjust safely.
EarningsRLYB reported a 2Q25 net loss of $9.7M.
Program DiscontinuationRallybio has announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Rallybio News
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $2.41 and its highest was $17.57 in the past 12 months.
What is Rallybio’s market cap?
Rallybio’s market cap is $84.27M.
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on May 12, 2026. The company reported -$1.455 earnings per share for the quarter, missing the consensus estimate of -$1.2 by -$0.255.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Overvalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -1.28.
How many shares outstanding does Rallybio have?
Rallybio has 5,300,039 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$1.455 in its last earnings report, missing expectations of -$1.2. Following the earnings report the stock price went up 0.214%.
Which hedge fund is a major shareholder of Rallybio?
Currently, no hedge funds are holding shares in RLYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rallybio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.80%
12-Months-Change
Fundamentals
Return on Equity
-14.39%
Trailing 12-Months
Asset Growth
-6.06%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Technical Analysis
Moleculin Biotech
―
Aptevo Therapeutics
―
Citius Pharmaceuticals
―
Processa Pharmaceuticals
―
Allarity Therapeutics
―